Observational Study for Fatty Liver Disease

Recruiting at 17 trial locations

Overseen By Ellie Michalski

Age: Any Age

Sex: Any

Trial Phase: Academic

Sponsor: Target PharmaSolutions, Inc.

Disqualifiers: Inability to provide consent

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

15000 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial focuses on understanding nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), liver conditions that can occur in individuals who consume little alcohol. Researchers aim to observe the progression of these diseases and evaluate the effectiveness of current and future treatments in real-life settings. The trial is open to anyone aged 2 or older who has been diagnosed with NAFLD or NASH by their doctor. This study seeks to enhance the safety and effectiveness of treatments for these liver conditions. As a Phase 3 trial, it represents the final step before FDA approval, offering participants the opportunity to contribute to the development of potentially groundbreaking treatments.

Why are researchers excited about this trial?

Researchers are excited about this trial because it aims to comprehensively understand the entire spectrum of nonalcoholic fatty liver disease (NAFLD), including nonalcoholic steatohepatitis (NASH) and related conditions. Unlike standard treatments that focus on specific stages or aspects of the disease, this observational study seeks to gather data across all stages, potentially uncovering new insights into disease progression and management. By exploring diverse patient experiences and conditions, the study could lead to the development of more targeted and effective therapies in the future.

Are You a Good Fit for This Trial?

Inclusion Criteria

1. Adults and children (age 2 or older) being managed or treated for nonalcoholic fatty liver disease. Diagnosis is based on the clinical judgement of the care provider.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Observational

Participants are observed for the natural history of NASH and related conditions, and the safety and effectiveness of current and future therapies are assessed

10 years

Follow-up

Participants are monitored for safety and effectiveness after observational period

1 year

What Are the Treatments Tested in This Trial?

Who Is Running the Clinical Trial?

Target PharmaSolutions, Inc.

Lead Sponsor

Trials

17

Recruited

5,667,000+